Sophie Cousin

Bordeaux, 33076, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 106 publications

Estimating Metastatic Disease Heterogeneity Using Radiomics-based Lesion Clustering and Heterogeneity Index - Application in Lung Adenocarcinoma Patients and Correlations With Patient Outcomes.

Estimating Metastatic Disease Heterogeneity Using Radiomics-based Lesion Clustering and Heterogeneity Index - Application in Lung Adenocarcinoma Patients and Correlations With Patient Outcomes.

Journal: Journal of imaging informatics in medicine
Published: March 31, 2026

Epileptogenic Brain Metastasis Early Positive on 18FDG PET/CT Compared to MRI.

Epileptogenic Brain Metastasis Early Positive on 18FDG PET/CT Compared to MRI.

Journal: Clinical nuclear medicine
Published: February 16, 2026

Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics Review.

Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics Review.

Journal: Cancers
Published: December 31, 2025

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2025

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

Journal: Clinical lung cancer
Published: October 30, 2025

Single and multi-site CT-based radiogenomics analysis of metastatic lung adenocarcinoma and correlations with outcome.

Single and multi-site CT-based radiogenomics analysis of metastatic lung adenocarcinoma and correlations with outcome.

Journal: European radiology
Published: September 11, 2025

Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer.

Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer.

Journal: Frontiers in oncology
Published: July 29, 2025

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.

Journal: Cancer cell
Published: July 07, 2025

Interpreting immunogenicity in oncology clinical trials.

Interpreting immunogenicity in oncology clinical trials.

Journal: Cancer treatment reviews
Published: June 12, 2025

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

Journal: ESMO open
Published: June 06, 2025

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

Journal: ESMO open
Published: May 22, 2025

Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.

Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.

Journal: The Lancet. Oncology
Published: January 27, 2025
Showing 1-12 of 106

Last Updated: 09/26/2026